PTX Share Price Performance
AU$0.05
0.00 (6.38%)
Price AU$0.05
Share PriceAU$0.05
Prescient Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
PTX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Prescient Therapeutics Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.007
- 100.00%
- -168.09%
- 0%
About PTX
- Founded
- 1986
- Employees
- n/a
- CEO
- WebsiteView website
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
